Enhancing Reliable Prostate Lesion Detection: Integrating Multi-Expert Annotations and Tailored nnU-Net Ensemble Learning Strategies增强前列腺病变可靠检测:整合多专家注释和定制化的nnU-Net集成学习策略Applied Sciences-BaselIF2.52026-04-180OA
Neuroimaging in post-traumatic stress disorder: a narrative reviewARCHIVES OF MEDICAL SCIENCEIF3.32024-06-070OAAI
Apparent diffusion coefficient value of normal appearing white matter may predict neda in MS patients treated with interferon-βEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010PRE
The relationship between stigma and social discrimination and self-esteem, wellbeing and quality of life in hospitalized people with mental disordersEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010PRE
MRI Protocol for Pituitary Assessment in Children with Growth or Puberty Disorders-Is Gadolinium Contrast Administration Actually Needed?JOURNAL OF CLINICAL MEDICINEIF2.92021-10-062OAAI
Apparent diffusion coefficient value of normal appearing white matter in prediction of NEDA loss in MS patients treated with interferon-βEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72020-11-010PREAI
The role of ADC values within the normal-appearing brain in the prognosis of multiple sclerosis activity during interferon-β therapy in the 3-year follow-up: a preliminary reportSCIENTIFIC REPORTSIF3.92020-07-300OAAI
Normal pressure hydrocephalus as a possible reversible cause of dementia, neuroimaging findingsEUROPEAN PSYCHIATRYIF6.72020-03-231PREAI
Apparent diffusion coefficient measurements in normal appearing white matter may support the differential diagnosis between multiple sclerosis lesions and other white matter hyperintensitiesJOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22019-02-013PREAI
Changes of diffusion in normal appearing white matter during treatment with interferon-β are not associated with clinical course of multiple sclerosisEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72019-01-010PREAI
Searching for clinical and radiological predictors of response to INF-Beta therapy in patients with multiple sclerosisEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72019-01-010PREAI
Do metabolic parameters of posterior cingulate gyrus in multiple sclerosis correlate with the duration of the disease?EUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
Does brain magnetic resonance spectroscopy allow the detection of metabolite changes during immunomodulatory therapy in multiple sclerosis?EUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
Magnetic resonance spectroscopy as a marker of neuronal activity within normal-appearing grey matter in patients with multiple sclerosis before treatmentEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72016-10-010PREAI
Apparent diffusion coefficient values do not correlate with the duration of the disease in patients with multiple sclerosis treated with interferon betaEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72016-10-010PREAI
Can initial MRI spectroscopy be useful in prediction of response to multiple sclerosis treatment with interferon beta?EUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72016-03-010PREAI
Changes in apparent diffusion coefficient values in patients with multiple sclerosis with regard to treatment with interferon betaEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72015-09-011PREAI
Changes in brain metabolism during multiple sclerosis treatment with interferon beta: evaluation in magnetic resonance spectroscopyEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72014-10-010PREAI